Abstract
Chronic obstructive pulmonary disease (COPD) is a long-term lung illness that affects both the bronchioles and distal alveoli. COPD is an extremely common outpatient global condition, which carries an immense socio- economic burden that is only to increase over the subsequent years. While preventable and treatable, it remains a leading cause of death worldwide. Optimizing pharmacologic management is central to improving patient outcomes and quality of life, yet therapeutic decisions continue to evolve as evidence expands. This review synthesizes current literature and guideline recommendations on the pharmacologic management of stable COPD patients in the outpatient setting, encompassing the role of bronchodilators, inhaled corticosteroids, anti-inflammatory agents, phosphodiesterase inhibitors, and emerging biologics. In addition, we discuss the clinical relevance and evidence surrounding the use of suppressive antibiotics, systemic corticosteroids, mucolytics, and antileukotrienes as adjunctive therapies in selected patients. Evidence from pivotal trials supports dual bronchodilator therapy (long-acting muscarinic antagonists (LAMA)/ long-acting Beta-2 agonists (LABA)) as first-line treatment for most patients, with escalation to triple therapy (LAMA/LABA/inhaled Corticosteroids (ICS)) for those with persistent symptoms or exacerbations, particularly among individuals with higher blood eosinophil counts. Chronic macrolide use, roflumilast, and novel agents such as ensifentrine and dupilumab have further expanded the therapeutic landscape, targeting inflammation and exacerbation prevention in selected phenotypes. Collectively, current data emphasize a personalized, stepwise approach to COPD management, one guided by symptom burden, exacerbation risk, and biomarker profiling, while highlighting the need for continued research into precision therapies and optimal de-escalation strategies to balance efficacy, safety, and cost- effectiveness.